Portal de Periódicos da CAPES

Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus

2013; Elsevier BV; Volume: 111; Issue: 8 Linguagem: Inglês

10.1016/j.amjcard.2012.12.037

1879-1913

Eliano Pio Navarese, Antonino Buffon, Felicita Andreotti, Marek Koziński, Nicky J. Welton, Tomasz Fabiszak, Salvatore Caputo, Grzegorz Grześk, Aldona Kubica, Iwona Świątkiewicz, Adam Sukiennik, Malte Kelm, Stefano De Servi, Jacek Kubica,

Computational Drug Discovery Methods

Recent reports indicate that statins are associated with an increased risk for new-onset diabetes mellitus (DM) compared with placebo and that this relation is dose dependent. The aim of this study was to perform a comprehensive network meta-analysis of randomized controlled trials (RCTs) investigating the impact of different types and doses of statins on new-onset DM. RCTs comparing different types and doses of statins with placebo were searched for using the MEDLINE, Embase, and Cochrane databases. A search of RCTs pertinent to this meta-analysis covering the period from November 1994 to October 2012 was conducted by 2 independent investigators using the MEDLINE, Cochrane, Google Scholar, and Embase databases as well as abstracts and presentations from major cardiovascular meetings. Seventeen RCTs reporting the incidence of new-onset DM during statin treatment and including a total of 113,394 patients were identified. The RCTs compared either a statin versus placebo or high-dose versus moderate-dose statin therapy. Among different statins, pravastatin 40 mg/day was associated with the lowest risk for new-onset DM compared with placebo (odds ratio 1.07, 95% credible interval 0.86 to 1.30). Conversely, rosuvastatin 20 mg/day was numerically associated with 25% increased risk for DM compared with placebo (odds ratio 1.25, 95% credible interval 0.82 to 1.90). The impact on DM appeared to be intermediate with atorvastatin 80 mg/day compared with placebo (odds ratio 1.15, 95% credible interval 0.90 to 1.50). These findings were replicated at moderate doses. In conclusion, different types and doses of statins show different potential to increase the incidence of DM. Recent reports indicate that statins are associated with an increased risk for new-onset diabetes mellitus (DM) compared with placebo and that this relation is dose dependent. The aim of this study was to perform a comprehensive network meta-analysis of randomized controlled trials (RCTs) investigating the impact of different types and doses of statins on new-onset DM. RCTs comparing different types and doses of statins with placebo were searched for using the MEDLINE, Embase, and Cochrane databases. A search of RCTs pertinent to this meta-analysis covering the period from November 1994 to October 2012 was conducted by 2 independent investigators using the MEDLINE, Cochrane, Google Scholar, and Embase databases as well as abstracts and presentations from major cardiovascular meetings. Seventeen RCTs reporting the incidence of new-onset DM during statin treatment and including a total of 113,394 patients were identified. The RCTs compared either a statin versus placebo or high-dose versus moderate-dose statin therapy. Among different statins, pravastatin 40 mg/day was associated with the lowest risk for new-onset DM compared with placebo (odds ratio 1.07, 95% credible interval 0.86 to 1.30). Conversely, rosuvastatin 20 mg/day was numerically associated with 25% increased risk for DM compared with placebo (odds ratio 1.25, 95% credible interval 0.82 to 1.90). The impact on DM appeared to be intermediate with atorvastatin 80 mg/day compared with placebo (odds ratio 1.15, 95% credible interval 0.90 to 1.50). These findings were replicated at moderate doses. In conclusion, different types and doses of statins show different potential to increase the incidence of DM. The Effect of Statin on the Incidence of Diabetes MellitusAmerican Journal of CardiologyVol. 112Issue 4PreviewNavarese et al recently reported a meta-analysis of randomized controlled trials concerning the effect of various types and doses of statins on new-onset diabetes mellitus (DM). The authors concluded that pravastatin 40 mg/day was associated with the lowest risk for new-onset DM compared with placebo.1 Carter et al reported a population-based cohort study concerning the effect of various types and doses of statins on new-onset DM by setting pravastatin as a control. Although the clinical evidence was weaker than that in randomized controlled trials, these authors concluded that higher-potency statins might be contributed to the increase of new-onset DM. Full-Text PDF